Dicerna Pharmaceuticals Stock Forecast, Price & News

Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

Is Dicerna Pharmaceuticals a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Dicerna Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DRNA, but not buy additional shares or sell existing shares.
View analyst ratings for Dicerna Pharmaceuticals or view top-rated stocks.

How has Dicerna Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DRNA shares have increased by 126.4% and is now trading at $38.22.
View which stocks have been most impacted by COVID-19.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Dicerna Pharmaceuticals.

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.19. The biopharmaceutical company had revenue of $62.95 million for the quarter, compared to analysts' expectations of $58.83 million. Dicerna Pharmaceuticals had a negative net margin of 64.53% and a negative trailing twelve-month return on equity of 103.08%. During the same period in the previous year, the business posted ($0.29) EPS.
View Dicerna Pharmaceuticals' earnings history.

What price target have analysts set for DRNA?

11 brokers have issued 12 month target prices for Dicerna Pharmaceuticals' stock. Their forecasts range from $25.00 to $47.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $35.31 in the next twelve months. This suggests that the stock has a possible downside of 7.6%.
View analysts' price targets for Dicerna Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the following people:

• Douglas M. Fambrough, President, Chief Executive Officer & Director
• James B. Weissman, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
• Douglas W. Pagán, Chief Financial Officer
• Bob D. Brown, Chief Scientific Officer (LinkedIn Profile)
• Shreeram Aradhye, Chief Medical Officer & Executive Vice President (LinkedIn Profile)

What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO?

35 employees have rated Dicerna Pharmaceuticals CEO Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among Dicerna Pharmaceuticals' employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Dicerna Pharmaceuticals' key competitors?

Some companies that are related to Dicerna Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), United Therapeutics (UTHR), Jazz Pharmaceuticals (JAZZ), Grifols (GRFS), Organon & Co. (OGN), Biohaven Pharmaceutical (BHVN), Maravai LifeSciences (MRVI), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Mirati Therapeutics (MRTX), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT) and Arrowhead Pharmaceuticals (ARWR).
View all of DRNA's competitors.

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD).

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $38.22.

How much money does Dicerna Pharmaceuticals make?

Dicerna Pharmaceuticals has a market capitalization of $2.99 billion and generates $164.31 million in revenue each year. The biopharmaceutical company earns $-112.75 million in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Dicerna Pharmaceuticals have?

Dicerna Pharmaceuticals employs 302 workers across the globe.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Where are Dicerna Pharmaceuticals' headquarters?

Dicerna Pharmaceuticals is headquartered at 33 HAYDEN AVENUE, LEXINGTON MA, 02421.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at (617) 621-8097, via email at [email protected], or via fax at 617-612-6298.